These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8521893)

  • 1. Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2).
    Jørgensen T; Müller C; Kaalhus O; Danielsen HE; Tveter KJ
    Eur Urol; 1995; 28(1):40-6. PubMed ID: 8521893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2.
    Jørgensen T; Tveter KJ; Jørgensen LH
    Eur Urol; 1993; 24(4):466-70. PubMed ID: 8287887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan.
    Soloway MS; Hardeman SW; Hickey D; Raymond J; Todd B; Soloway S; Moinuddin M
    Cancer; 1988 Jan; 61(1):195-202. PubMed ID: 3334948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
    Sylvester RJ; Denis L; de Voogt H
    Eur Urol; 1998; 33(2):134-43. PubMed ID: 9519354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI) study.
    Nakajima K; Kaneko G; Takahashi S; Matsuyama H; Shiina H; Ichikawa T; Horikoshi H; Hashine K; Sugiyama Y; Miyao T; Kamiyama M; Harada K; Ito A; Mizokami A;
    Int J Urol; 2018 May; 25(5):492-499. PubMed ID: 29633398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy.
    Rigaud J; Tiguert R; Le Normand L; Karam G; Glemain P; Buzelin JM; Bouchot O
    J Urol; 2002 Oct; 168(4 Pt 1):1423-6. PubMed ID: 12352409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
    Nair B; Wilt T; MacDonald R; Rutks I
    Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group.
    Janknegt RA; Boon TA; van de Beek C; Grob P
    Urology; 1997 Mar; 49(3):411-20. PubMed ID: 9123707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cyproterone acetate. Its value in the treatment of prostatic cancer. Apropos of 45 cases].
    Tobelem G; Arvis G
    Therapie; 1988 May; 43(3):179-82. PubMed ID: 2971278
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic significance of bone metastases in patients with metastatic prostate cancer.
    Yamashita K; Denno K; Ueda T; Komatsubara Y; Kotake T; Usami M; Maeda O; Nakano S; Hasegawa Y
    Cancer; 1993 Feb; 71(4):1297-302. PubMed ID: 8435807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of bone scans in advanced prostate carcinoma using fully automated and semi-automated bone scan index methods.
    Takahashi Y; Yoshimura M; Suzuki K; Hashimoto T; Hirose H; Uchida K; Inoue S; Koizumi K; Tokuuye K
    Ann Nucl Med; 2012 Aug; 26(7):586-93. PubMed ID: 22744807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta.
    Ernst DS; Hanson J; Venner PM
    J Urol; 1991 Aug; 146(2):372-6. PubMed ID: 1856934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.
    Smith PH; Bono A; Calais da Silva F; Debruyne F; Denis L; Robinson P; Sylvester R; Armitage TG
    Cancer; 1990 Sep; 66(5 Suppl):1009-16. PubMed ID: 2144203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
    Prescrire Int; 2013 Feb; 22(135):48-51. PubMed ID: 23444510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate.
    Robinson MR; Smith PH; Richards B; Newling DW; de Pauw M; Sylvester R
    Eur Urol; 1995; 28(4):273-83. PubMed ID: 8575493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
    Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
    N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of specific prostatic antigen on the rationalization of the use of bone gammagraphies in the follow-up of hormone-treated non- metastatic prostatic cancer].
    Morote Robles J; Reig Ruiz C; Vila Barja J; López Pacios MA; de Torres Mateos JA; Soler Roselló A
    Actas Urol Esp; 1993 May; 17(5):292-4. PubMed ID: 7688176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of raised prostatic acid phosphatase and negative skeletal scintigraphy in prostatic cancer.
    Goodman CM; Cumming JA; Ritchie AW; Chisholm GD
    Br J Urol; 1991 Jun; 67(6):622-5. PubMed ID: 2070208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).
    Bertagna C; De Géry A; Hucher M; François JP; Zanirato J
    Br J Urol; 1994 Apr; 73(4):396-402. PubMed ID: 8199827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.